Playlist


Turkmenistan Airlines announces temporary suspension of scheduled flights to UAE destinations
06 Jun. 08:47The national air carrier of Turkmenistan has implemented operational adjustments to its international flight schedule due to localized airspace restrictions in the Islamic Republic of Iran. To guarantee the overarching safety of its flight operations and passengers, the airline has suspended all scheduled services on the Ashgabat — Dubai — Ashgabat and Ashgabat — Abu Dhabi — Ashgabat routes until mid-June.
Passengers affected by these seasonal cancellations are eligible for a comprehensive institutional refund policy. The airline is offering full monetary compensation for unused tickets without extracting any administrative penalties, cancellation fees, or processing deductions. Alternatively, travelers retain the right to rebook their itineraries to the nearest available dates entirely free of charge at any corporate ticketing office.
For individuals who finalized their bookings via the carrier's digital portal or associated electronic payment networks, the reimbursement will be managed through automated banking channels. The funds are scheduled to be credited directly back to the original payment cards used during the booking sequence. The aviation authority has issued a formal apology for the logistical disruption and advises clients to monitor upcoming updates via corporate communication networks.
To facilitate customer support during this period, the airline has activated dedicated hotlines and digital helpdesks across its regional branches. Specialized helplines are currently operational both in Dubai and within Turkmenistan to process inquiries regarding ticket management and itinerary changes. Passengers can utilize these designated voice and electronic mailing tools to interface with corporate service agents.
Also read


American researchers have initiated trials for a new pharmaceutical compound designated as ENV-308, designed to replicate the physiological effects of intensive physical training. Formulated in tablet form, the medication aims to trigger the body's metabolic responses similar to those experienced during exercise.
Scientists at Enveda utilized the Lac-Phe molecule as the core component for this development. Naturally produced by the body during vigorous exertion, this molecule transmits signals to the brain that suppress appetite and signal satiety.
Preclinical trials conducted on animal models demonstrated significant positive results. The tablets effectively reduced hunger levels and facilitated weight loss while entirely preserving existing muscle mass.
Researchers have successfully completed the first phase of clinical trials, confirming the safety of the drug for human use. Future studies will focus on evaluating the compound's impact on metabolism and exploring its potential combination with established therapeutics such as Ozempic.